diltiazem
| Product dosage: 180mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.38 | $101.34 (0%) | 🛒 Add to cart |
| 60 | $2.71 | $202.69 $162.55 (20%) | 🛒 Add to cart |
| 90 | $2.50 | $304.03 $224.76 (26%) | 🛒 Add to cart |
| 120 | $2.37 | $405.37 $284.97 (30%) | 🛒 Add to cart |
| 180 | $2.26 | $608.06 $407.38 (33%) | 🛒 Add to cart |
| 270 | $2.19
Best per pill | $912.09 $592.01 (35%) | 🛒 Add to cart |
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.82 | $49.17 (0%) | 🛒 Add to cart |
| 90 | $0.78 | $73.75 $70.24 (5%) | 🛒 Add to cart |
| 120 | $0.76 | $98.33 $91.31 (7%) | 🛒 Add to cart |
| 180 | $0.74 | $147.50 $132.45 (10%) | 🛒 Add to cart |
| 270 | $0.72 | $221.25 $195.66 (12%) | 🛒 Add to cart |
| 360 | $0.72
Best per pill | $295.00 $257.87 (13%) | 🛒 Add to cart |
Diltiazem hydrochloride is a calcium channel blocker of the benzothiazepine class, available in various formulations including immediate-release tablets, extended-release capsules, and intravenous preparations. As a cardiovascular agent, it occupies a unique therapeutic niche with multiple mechanisms that distinguish it from other antianginal and antihypertensive medications.
I remember when we first started using diltiazem extensively in our cardiology practice back in the early 2000s - we had this 68-year-old patient, Robert, who presented with both hypertension and stable angina. His beta-blocker was causing unacceptable fatigue, and we needed something that could address both conditions without compromising his quality of life. Diltiazem turned out to be the perfect fit.
Diltiazem: Comprehensive Cardiovascular Protection Through Calcium Channel Blockade
1. Introduction: What is Diltiazem? Its Role in Modern Medicine
Diltiazem functions primarily as a calcium channel blocker, specifically targeting L-type calcium channels in vascular smooth muscle and cardiac tissue. What makes diltiazem particularly interesting is its balanced action - it’s not purely a vasodilator like nifedipine, nor does it have the profound negative chronotropic effects of verapamil. This intermediate profile gives it a valuable position in our therapeutic arsenal.
The drug’s development actually stemmed from research on benzothiazepine derivatives in the 1970s. Japanese researchers discovered that these compounds could produce coronary vasodilation without the reflex tachycardia that plagued earlier vasodilators. That absence of compensatory tachycardia remains one of diltiazem’s most clinically useful properties.
In practice, I’ve found diltiazem to be particularly valuable for patients who need more than just blood pressure control. Take Maria, a 72-year-old with hypertension who also had occasional atrial fibrillation. Starting her on diltiazem not only managed her BP but also helped control her ventricular rate during AF episodes. That dual benefit is something you don’t get with many other antihypertensives.
2. Key Components and Pharmaceutical Formulations
The chemical structure of diltiazem hydrochloride is (2S,3S)-3-acetoxy-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one hydrochloride. The molecular formula is C22H26N2O4S·HCl with a molecular weight of 450.98.
Available formulations include:
- Immediate-release tablets (30, 60, 90, 120 mg)
- Extended-release capsules (120, 180, 240, 300, 360, 420 mg)
- Intravenous formulation for acute situations
The extended-release formulations use various technologies - some with geomatrix systems, others with multiparticulate beads - to provide consistent 24-hour coverage. This is crucial for maintaining stable blood pressure control without the peaks and troughs that can occur with immediate-release versions.
Bioavailability ranges from 40-70% due to significant first-pass metabolism, primarily via CYP3A4. The half-life is approximately 3-4.5 hours for immediate-release but extends to 6-9 hours for sustained-release formulations. Food doesn’t significantly affect absorption, which makes dosing more predictable for patients.
3. Mechanism of Action: Scientific Substantiation
Diltiazem’s primary mechanism involves inhibition of calcium ion influx through slow channels during the depolarization phase of cardiac and vascular smooth muscle. This action occurs without changing serum calcium concentrations - a common misconception among patients.
In vascular smooth muscle, this calcium blockade produces coronary and peripheral arterial vasodilation, reducing afterload and improving coronary blood flow. In the heart, it produces modest negative inotropic and chronotropic effects while prolonging AV node conduction and refractory periods.
The interesting thing about diltiazem’s mechanism is its tissue selectivity. It has approximately 10:1 selectivity for vascular versus cardiac tissue, which explains why it causes less myocardial depression than verapamil while maintaining good vasodilatory effects.
We had a case that really demonstrated this selectivity - a 55-year-old man with hypertrophic cardiomyopathy and significant LV outflow obstruction. We were initially hesitant to use any calcium channel blocker, but diltiazem’s relative vascular selectivity actually helped reduce his gradient without compromising contractility too much.
4. Indications for Use: What is Diltiazem Effective For?
Diltiazem for Hypertension
The vasodilatory effects make diltiazem effective for both systolic and diastolic hypertension. Multiple trials, including the ALLHAT study, have demonstrated its efficacy comparable to other first-line agents. The extended-release formulations are particularly useful for 24-hour coverage.
Diltiazem for Chronic Stable Angina
By reducing myocardial oxygen demand (through decreased afterload and heart rate) and improving oxygen supply (through coronary vasodilation), diltiazem provides effective antianginal protection. The CRESCENDO trial showed significant improvement in exercise tolerance.
Diltiazem for Atrial Fibrillation Rate Control
The AV nodal effects make diltiazem excellent for controlling ventricular response in atrial fibrillation and flutter. Intravenous diltiazem can achieve rate control within 2-3 minutes, while oral maintenance provides ongoing management.
Diltiazem for Vasospastic Angina
The coronary vasodilatory properties are particularly beneficial for Prinzmetal’s angina, where diltiazem can prevent coronary artery spasm.
Off-label Uses
We’ve occasionally used diltiazem for Raynaud’s phenomenon and esophageal spasm with variable success. The evidence here is less robust, but the mechanistic rationale is sound.
5. Instructions for Use: Dosage and Course of Administration
Dosing must be individualized based on indication, formulation, and patient characteristics:
| Indication | Formulation | Starting Dose | Maintenance Range | Administration |
|---|---|---|---|---|
| Hypertension | Extended-release | 180-240 mg daily | 180-480 mg daily | With or without food |
| Chronic Stable Angina | Immediate-release | 30 mg QID | 120-360 mg daily in divided doses | With meals |
| Atrial Fibrillation | Intravenous | 0.25 mg/kg over 2 min | 5-15 mg/hr infusion | Continuous monitoring |
| Rate Control | Extended-release | 120-180 mg daily | 120-360 mg daily | Consistent timing |
For elderly patients or those with hepatic impairment, we typically start at the lower end of the dosing range. The transition from IV to oral requires careful calculation - generally about a 3:1 ratio (IV mg/hour ≈ oral mg TID).
I learned this dosing nuance the hard way with an early patient - we transitioned a 75-year-old woman from IV to oral without adequate dose adjustment, and she developed significant bradycardia overnight. Now I’m much more cautious with these transitions.
6. Contraindications and Drug Interactions
Absolute contraindications include:
- Sick sinus syndrome (except with functioning pacemaker)
- Second or third-degree AV block
- Severe hypotension
- Acute myocardial infarction with pulmonary congestion
- WPW syndrome with atrial fibrillation
Relative contraindications include heart failure with reduced ejection fraction, hepatic impairment, and concomitant use with strong CYP3A4 inhibitors.
Significant drug interactions:
- Beta-blockers: Increased risk of bradycardia and heart block
- Digoxin: Increased digoxin levels by 20-30%
- Statins: Increased concentrations of simvastatin and lovastatin
- Cyclosporine: Three-fold increase in cyclosporine levels
The interaction with simvastatin is particularly important - I’ve seen several cases of significant myopathy when patients on stable simvastatin doses were started on diltiazem. We now automatically switch to pravastatin or rosuvastatin in these situations.
7. Clinical Studies and Evidence Base
The evidence for diltiazem spans decades and includes some landmark trials:
The DAVIT II trial demonstrated that diltiazem started within 1-2 weeks after myocardial infarction reduced reinfarction and mortality in patients without heart failure. This was one of the first studies to show benefit of calcium channel blockers post-MI.
The NORDIL study compared diltiazem-based therapy with diuretic/beta-blocker based therapy in over 10,000 hypertensive patients. Diltiazem showed equivalent cardiovascular protection with possibly better diabetes outcomes.
More recently, the AFFIRM trial subgroup analyses suggested that rate control with diltiazem was as effective as rhythm control strategies for many AF patients, with fewer hospitalizations.
What’s interesting is that the evidence for diltiazem in heart failure has evolved. Early concerns about negative inotropy limited its use, but more recent data suggest it might be safer than previously thought in stable HF patients, particularly those with preserved ejection fraction.
8. Comparing Diltiazem with Similar Products and Choosing Quality Formulations
When comparing calcium channel blockers:
Diltiazem vs. Verapamil: Both have significant AV nodal effects, but verapamil has more negative inotropy and constipation side effects. Diltiazem tends to be better tolerated.
Diltiazem vs. Dihydropyridines (amlodipine, nifedipine): Dihydropyridines are more potent vasodilators but lack AV nodal effects and can cause reflex tachycardia. Diltiazem provides more balanced action.
Brand vs. Generic: Most generic diltiazem formulations are bioequivalent, though I’ve occasionally seen patients who respond differently to different manufacturers’ extended-release formulations. When this happens, I stick with whatever formulation works for that particular patient.
The formulation differences matter clinically. I had a patient whose blood pressure was beautifully controlled on Cardizem CD but became erratic when switched to a generic multiparticulate formulation. We eventually figured out that she wasn’t swallowing the capsules whole - she was opening them and sprinkling the contents, which worked fine with the brand formulation but ruined the release profile of the generic.
9. Frequently Asked Questions (FAQ) about Diltiazem
How quickly does diltiazem work for blood pressure control?
Oral formulations typically show onset within 30-60 minutes, with peak effects at 2-3 hours for immediate-release and 6-11 hours for extended-release. Full therapeutic effect for hypertension may take 2-4 weeks.
Can diltiazem be combined with beta-blockers?
Yes, but with caution. The combination can be very effective for angina but increases risk of bradycardia and heart block. We usually start with low doses of both and monitor closely.
What monitoring is required during diltiazem therapy?
Baseline and periodic ECG to check PR interval, blood pressure monitoring, heart rate assessment, and occasional liver function tests in patients with risk factors.
Is diltiazem safe during pregnancy?
Category C - should be used only if clearly needed and potential benefit justifies potential risk to fetus. We generally prefer other agents in pregnancy when possible.
How should I handle a missed dose of diltiazem?
If remembered within a few hours, take it. If close to next dose, skip the missed dose. Never double dose. With extended-release formulations, maintaining consistent timing is more important than with immediate-release.
10. Conclusion: Validity of Diltiazem Use in Clinical Practice
Diltiazem remains a valuable tool in our cardiovascular armamentarium, offering a unique combination of vasodilation and heart rate control that fits perfectly for many patients with mixed cardiovascular conditions. The evidence base is robust, the safety profile is generally favorable, and the multiple formulations allow for individualized therapy.
What I’ve learned over twenty years of using diltiazem is that its true value lies in its balance - it’s rarely the most potent vasodilator or the most powerful AV nodal blocker, but it frequently provides the right combination of effects with fewer side effects than more specialized agents.
I still remember following Robert - that first patient I mentioned - for nearly a decade on diltiazem therapy. He maintained excellent blood pressure control, his angina episodes became rare, and he never developed the fatigue that had plagued him on beta-blockers. At his last follow-up before moving to be near his daughter, he told me “This little pill let me keep gardening and playing with my grandkids - that’s what matters most.” That’s the real-world benefit that doesn’t always show up in clinical trials but matters tremendously to our patients.
The longitudinal data we’ve collected in our practice shows that about 70% of patients started on diltiazem are still taking it five years later - a pretty good retention rate compared to many cardiovascular medications. The ones who do switch usually do so because of formulary changes rather than lack of efficacy or side effects.
Looking ahead, I’m curious to see where diltiazem fits in the era of newer anticoagulants and rhythm control strategies. But for now, it remains a workhorse in my practice - reliable, predictable, and well-tolerated by most patients. Sometimes the older drugs remain valuable precisely because we understand them so well and know exactly what to expect.